pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$ESPREsperion Therapeutics, Inc.

$ESPR
Ann Arbor, MI, USupdated 4mo ago

Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.

SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
6
marketed
2
phase 3
0
catalysts ytd
2
approvals ytd
2
recalls ytd
0

Pipeline(6)

pipeline depth6 products
Preclinical: 2Marketed: 2Unknown: 2
2Preclinical2Marketed2Unknown
Marketed
(bempedoic acid + ezetimibe)
Heterozygous Familial Hypercholesterolemia (heFH)
Marketed
bempedoic acid
Heterozygous Familial Hypercholesterolemia (heFH)
ATP-citrate synthase
Preclinical
(bempedoic acid + ezetimibe + rosuvastatin)
Cardiovascular Risk Factors
Preclinical
ESP-2001
Primary Sclerosing Cholangitis
drug
NEXLETOL
1 INDICATIONS AND USAGE NEXLETOL is indicated: to reduce…
ATP-citrate synthase
drug
NEXLIZET
1 INDICATIONS AND USAGE NEXLIZET, a combination of bemped…
ATP-citrate synthase

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →

Active trials

  • phase2A Clinical Study in Children With Heterozygous Familial Hypercholesterolemia (HeFH) Aged 6 to 17 Treated Once Daily With Bempedoic Acid Oral Dosing (CLEAR Path 1)completedn=31
  • phase4Milk-Only Lactation Study to Evaluate the Concentration of Bempedoic Acid and Bempedoic Acid/Ezetimibe Fixed Combination Drug Product (FCDP) in the Breast Milk of Healthy Lactating Womencompletedn=16
  • —Bempedoic Acid Pregnancy Surveillance Programrecruitingn=20
  • phase3Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebocompletedn=13,970
🐶 Hiring Signal
No open roles indexed yet — view Esperion Therapeutics, Inc. jobs →

News

  • Summit’s ‘self-inflicted’ stumble; Esperion’s take-private deal
    Summit’s decision to conduct an interim analysis of a closely watched trial backfired. Elsewhere, Axsome got a much-needed label expansion and an FDA committee sided against an AstraZeneca breast c…
    biopharma_dive · 5mo ago
identifiers
ticker
$ESPR
SEC CIK
0001434868
country
US
source
sec_tickers
top tags
Cardiology3Hyperlipidemia2
mentioned in
1news items
entity-linker matched
Data sources
SEC EDGAR · openFDA
last refreshed 38m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?